Clinical and pharmacological group: & nbsp

ACE Inhibitors

Diuretics

Included in the formulation
  • Ko-Parnavel
    pills inwards 
    ATOLL, LLC     Russia
  • Ko Perineva®
    pills inwards 
    KRKA-RUS, LLC     Russia
  • Co-Benefit®
    pills inwards 
    KRKA-RUS, LLC     Russia
  • Noliprel®
    pills inwards 
  • Noliprel® A
    pills inwards 
  • Noliprel® A B-forte
    pills inwards 
  • Noliprel® A forte
    pills inwards 
  • Noliprel® forte
    pills inwards 
  • Perindapam®
    pills inwards 
    Sandoz d.     Slovenia
  • Perindid
    pills inwards 
  • GEDEON RICHTER, OJSC     Hungary
  • АТХ:

    C.09.B.A.04   Perindopril in combination with diuretics

    Pharmacodynamics:

    Combined antihypertensive drug

    Indapamide

    Diuretic, a derivative of sulfonamide. Inhibits the reabsorption of sodium in the renal tubules, increases the excretion of sodium and chlorine, enhancing diuresis.Selectively blocks "slow" calcium channels, reduces the overall peripheral resistance of blood vessels, increases the elasticity of the walls of the arteries. Has no effect on lipid metabolism (Lipoproteins of low density, high-density lipoproteins, triglycerides) and carbohydrates.

    Perindopril

    Blocking the conversion of angiotensin I in angiotensin II, resulting in a decrease in the release of norepinephrine from the endings of sympathetic fibers, the vasoconstrictor effect, the secretion of aldosterone by the adrenal cortex and increases the bradykinin content by reducing its inactivation by the angiotensin-converting enzyme.

    Bradykinin stimulates B2-cinin receptors of the vascular endothelium, which leads to the rapid release of prostacyclin and other vasodilating substances that cause relaxation of smooth muscles.

    Reduces the overall peripheral resistance of blood vessels, without affecting the heart rate.

    Pharmacokinetics:

    Indapamide

    After oral administration, the empty stomach is completely absorbed in the gastrointestinal tract. The maximum concentration in the blood plasma is reached after 1 hour. The connection with plasma proteins is 79%.Therapeutic effect develops 1-2 hours after the start of the procedure.

    Penetrates through the blood-brain and placental barrier, excreted in breast milk. Do not cumulate.

    Metabolism in the liver.

    The half-life is 18 hours. Elimination by the kidneys and with feces in the form of metabolites.

    Perindopril

    After oral administration, the fasted to 65-70% is absorbed in the gastrointestinal tract. The maximum concentration in the blood plasma is achieved in 3-4 hours. The connection with plasma proteins is 20%.

    Penetrates through the blood-brain and placental barrier, excreted in breast milk. Do not cumulate.

    Metabolism in the liver with the formation of one active metabolite - perindoprilata and five inactive metabolites.

    The elimination half-life is 1 hour. Half-life perindoprilata is 17 hours. Elimination by the kidneys.

    Indications:

    It is used for the treatment of arterial hypertension.

    IX.I10-I15.I15   Secondary Hypertension

    IX.I10-I15.I10   Essential [primary] hypertension

    Contraindications:

    Anuria, azotemia, hyperkalemia, stenosis of the renal arteries, liver failure, individual intolerance, age under 18 years.

    Carefully:

    Systemic diseases of connective tissue, stenocardia, renovascular hypertension, advanced age, hypersensitivity.

    Pregnancy and lactation:

    Recommendations for FDA - Category C. Contraindicated in pregnancy and lactation.

    Dosing and Administration:

    Inside 1 tablet once a day.

    The highest daily dose: 1 tablet.

    The highest single dose: 1 tablet.

    Side effects:

    Perindopril

    Central and peripheral nervous system: cerebral ischemia, headache, dizziness, anxiety, confusion, paresthesia.

    Hemopoietic system: anemia, leukopenia, thrombocytopenia, rarely - eosinophilia.

    Respiratory system: dry cough, bronchospasm, dyspnea, rhinorrhea, pharyngitis, dysphonia.

    The cardiovascular system: hyperkalemia, hyponatremia, orthostatic hypotension, syncope, tachycardia, angina pectoris, myocardial infarction.

    Digestive system: nausea, cholestatic jaundice, constipation, dry mouth.

    urinary system: hypercreatininaemia, proteinuria, increased urea levels, development or progression of chronic renal failure.

    Dermatological reactions: onycholysis, alopecia.

    Reproductive system: decreased potency.

    Allergic reactions.

    Indapamide

    Central and peripheral nervous system: headache, asthenia, nervousness, depression, irritability, anxiety, paresthesia.

    Respiratory system: pharyngitis, sinusitis, cough, sometimes - rhinitis.

    The cardiovascular system: arrhythmias, orthostatic hypotension, palpitation.

    Digestive system: anorexia, dry mouth, gastralgia, vomiting, constipation, diarrhea, pancreatitis.

    Dermatological reactions: hemorrhagic vasculitis.

    Sense organs: visual disturbances, conjunctivitis.

    urinary system: nocturia, polyuria.

    Reproductive system: decreased potency and libido.

    Allergic reactions.

    Overdose:

    Indapamide

    Drowsiness, dizziness, confusion, respiratory depression. In patients with cirrhosis - the development of hepatic coma.

    Treatment is symptomatic.

    Perindopril

    Pronounced decrease in blood pressure, electrolyte imbalance, bradycardia, cardiovascular shock, renal failure.

    Treatment: intravenous epinephrine, blood substitution solutions, hydrocortisone. Hemodialysis.

    Interaction:

    Perindopril

    Strengthens the hypoglycemic action of insulin and oral hypoglycemic drugs.

    Enhances the toxic effects of lithium preparations.

    Sodium chloride, non-steroidal anti-inflammatory drugs reduce the hypotensive effect of perindopril.

    With simultaneous use with potassium-sparing diuretics (amiloride, triamterene, spironolactone), products with a high content of potassium develops hyperkalemia.

    When used simultaneously with cytostatics, allopurinol, systemic glucocorticosteroids, procainamide, immunosuppressants increase the risk of developing leukopenia.

    With simultaneous use with drugs for general anesthesia and for local anesthesia, it is possible to develop arterial hypotension.

    Indapamide

    By reducing the excretion in the urine increases the concentration of lithium ions, which increases the risk of developing nephrotoxic action.

    Cardiac glycosides, saluretics, mineralo- and glucocorticoids, amphotericin B (with intravenous administration), tetracosactide, laxatives increase the state of acidosis.

    With simultaneous use with calcium preparations, hypercalcemia develops.

    Reduces the hypotensive effect of glucocorticosteroids, non-steroidal anti-inflammatory drugs, sympathomimetics, tetracosactide.

    Strengthens the hypotensive effect baclofen.

    With the simultaneous use of iodine-containing contrast agents, dehydration develops.

    Antipsychotic drugs and antidepressants strengthen the hypotensive effect, which can lead to orthostatic collapse.

    Reduces the effect of indirect anticoagulants by increasing the concentration of clotting factors, due to increased production of liver and reducing the volume of circulating blood.

    Strengthens the effect of nondepolarizing muscle relaxants.

    Special instructions:

    Monitoring of blood pressure, peripheral blood.

    With caution apply to individuals whose profession requires increased concentration and attention.

    Instructions
    Up